Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial

The Lancet Jul 17, 2019

Gerstein HC, et al. - In individuals with type 2 diabetes with and without previous cardiovascular disease and a wide range of glycemic control, researchers sought to examine how major adverse cardiovascular events are affected when the glucagon-like peptide-1 receptor agonist dulaglutide is added to their existing antihyperglycemic regimens. This multicenter, randomized, double-blind, placebo-controlled trial was conducted at 371 sites in 24 countries and included men and women aged at least 50 years with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors. They randomly assigned (1:1) 9,901 participants (mean age 66.2 years; median HbA 1c 7.2%; 4,589 [46.3%] women) to receive dulaglutide (n=4,949) or placebo (n=4,952). Outcomes suggest that consideration could be given to dulaglutide for managing glycemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors.

Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen